CL Use To Be Limited To Emergencies – India Official
This article was originally published in PharmAsia News
Executive Summary
If India uses a compulsory licensing policy for pharmaceuticals, it is likely to confine the procedure to emergency needs only. Recent CL applications, such as one filed by Natco Pharma to export cancer generics of Roche's Tarceva (erlotinib hydrochloride) and Pfizer's Sutent (sunitinib malate) to Nepal, are unlikely to be granted. A senior official of the patent-overseeing Department of Industrial Policy and Promotion said the agency favors CL only in cases of "an extraordinary problem" such as a widespread epidemic that needs an immediate solution. (Click here for more